The current valuation score of Neurocrine Biosciences Inc is 5.24, ranking 148 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 24.90, which is 521.30% below the recent high of 154.68 and 10.32% above the recent low of 22.33.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.